Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krishnaprasad Baby

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
F1000Research|November 18, 2020
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An <i>in silico</i> drug repurposing for COVID-19Krishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
European Journal of Pharmacology|February 4, 2021
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing studyKrishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
Archives of Medical Research|September 23, 2020
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing StudyKrishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
Inflammopharmacology|March 25, 2023
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosisNikitha Naomi Dsouza, Varun Alampady, Krishnaprasad Baby, et al.
Molecular Biology Reports|February 20, 2025
Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsJaya Aakriti, Megh Pravin Vithalkar, Swastika Maity, et al.
Life Sciences|March 9, 2025
Unveiling the potential of tankyrase I inhibitors for the treatment of type 2 diabetes mellitus: A hybrid approach using network pharmacology, 2D structural similarity, molecular docking, MD simulation and in-vitro studiesRuchi Yadav, Krishnaprasad Baby, Yogendra Nayak, et al.
F1000Research|February 11, 2025
Network pharmacology and in silico approaches to uncover multitargeted mechanism of action of Zingiber zerumbet rhizomes for the treatment of idiopathic pulmonary fibrosisBharath Harohalli Byregowda, Krishnaprasad Baby, Swastika Maity, et al.
Scientifica|April 29, 2025
Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus InfectionKrishnaprasad Baby, Megh Pravin Vithalkar, Somasish Ghosh Dastidar, et al.
F1000Research|December 26, 2025
Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanismsSwastika Maity, Krishnaprasad Baby, Bharath Harohalli Byregowda, et al.
Scientific Reports|May 16, 2023
Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancerKrishnaprasad Baby, Swastika Maity, Chetan Hasmukh Mehta, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
F1000Research|November 18, 2020
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An <i>in silico</i> drug repurposing for COVID-19Krishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
European Journal of Pharmacology|February 4, 2021
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing studyKrishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
Archives of Medical Research|September 23, 2020
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing StudyKrishnaprasad Baby, Swastika Maity, Chetan H Mehta, et al.
Inflammopharmacology|March 25, 2023
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosisNikitha Naomi Dsouza, Varun Alampady, Krishnaprasad Baby, et al.
Molecular Biology Reports|February 20, 2025
Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsJaya Aakriti, Megh Pravin Vithalkar, Swastika Maity, et al.
Life Sciences|March 9, 2025
Unveiling the potential of tankyrase I inhibitors for the treatment of type 2 diabetes mellitus: A hybrid approach using network pharmacology, 2D structural similarity, molecular docking, MD simulation and in-vitro studiesRuchi Yadav, Krishnaprasad Baby, Yogendra Nayak, et al.
F1000Research|February 11, 2025
Network pharmacology and in silico approaches to uncover multitargeted mechanism of action of Zingiber zerumbet rhizomes for the treatment of idiopathic pulmonary fibrosisBharath Harohalli Byregowda, Krishnaprasad Baby, Swastika Maity, et al.
Scientifica|April 29, 2025
Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus InfectionKrishnaprasad Baby, Megh Pravin Vithalkar, Somasish Ghosh Dastidar, et al.
F1000Research|December 26, 2025
Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanismsSwastika Maity, Krishnaprasad Baby, Bharath Harohalli Byregowda, et al.
Scientific Reports|May 16, 2023
Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancerKrishnaprasad Baby, Swastika Maity, Chetan Hasmukh Mehta, et al.
Pageof 2